Amgen Inc.
439.26USD
-8.0200 (-1.79%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on AMGN.
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 26.3B | 28.2B | 33.4B | 36.8B | 39.0B | 40.4B |
| Q1 | 6.2B | 6.1B | 7.4B | 8.1B | 8.6B | — |
| Q2 | 6.6B | 7.0B | 8.4B | 9.2B | 10.1B | — |
| Q3 | 6.7B | 6.9B | 8.5B | 9.6B | 10.1B | — |
| Q4 | 6.8B* | 8.2B* | 9.1B* | 9.9B* | 10.3B | — |
Revenue
| (USD) | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|
| FY | 12.11 | 12.49 | 7.56 | 14.23 | 23.03 | 24.49 |
| Q1 | 2.68 | 5.28 | -.210 | 3.20 | 3.34 | — |
| Q2 | 2.45 | 2.57 | 1.38 | 2.65 | 4.37 | — |
| Q3 | 3.98 | 3.22 | 5.22 | 5.93 | 5.79 | — |
| Q4 | 2.99* |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Cells marked * were synthesized from the annual filing less the year-to-date figures, because the quarter was not filed on its own. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
| 1.43* |
| 1.16* |
| 2.46* |
| 5.77 |
| — |
Debt level and coverage